Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis

Biol Psychiatry. 2011 Feb 1;69(3):208-17. doi: 10.1016/j.biopsych.2010.07.026. Epub 2010 Oct 15.

Abstract

Background: Subtypes of sigma (σ) receptors, σ₁ and σ₂, can be pharmacologically distinguished, and each may be involved in substance-abuse disorders. σ-Receptor antagonists block cocaine place conditioning and σ-receptor agonists are self-administered in rats that previously self-administered cocaine. Self-administration of abused drugs has been related to increased dopamine (DA) neurotransmission, however, σ-receptor agonist effects on mesolimbic DA are not fully characterized.

Methods: Receptor-binding studies assessed affinities of σ-receptor ligands for σ-receptor subtypes and the DA transporter; effects on DA transmission in the rat nucleus accumbens shell were assessed using in vivo microdialysis.

Results: Cocaine (.1-1.0 mg/kg intravenous [IV]), the nonselective σ(½)-receptor agonist DTG (1.0-5.6 mg/kg IV), and the selective σ₁-receptor agonist PRE-084 (.32-10 mg/kg IV) dose-dependently increased DA to ∼275%, ∼150%, and ∼160% maxima, respectively. DTG-induced stimulation of DA was antagonized by the nonselective σ(½)-receptor antagonist BD 1008 (10 mg/kg intraperitoneal [IP]) and the preferential σ₂-receptor antagonist SN 79 (1-3 mg/kg IP), but not by the preferential σ₁-receptor antagonist, BD 1063 (10-30 mg/kg IP). Neither PRE-084 nor cocaine was antagonized by BD 1063 or BD 1008.

Conclusions: σ-Receptor agonists stimulated DA in a brain area critical for reinforcing effects of cocaine. DTG effects on DA appear to be mediated by σ₂-receptors rather than σ₁-receptors. However, DA stimulation by cocaine or PRE-084 does not likely involve σ-receptors. The relatively low potency on DA transmission of the selective σ₁-receptor agonist, PRE-084, and its previously reported potent reinforcing effects, suggest a dopamine-independent reinforcing pathway that may contribute to substance-abuse disorders.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoxazoles / pharmacology
  • Cocaine / pharmacology
  • Dopamine / metabolism*
  • Dopamine Plasma Membrane Transport Proteins / antagonists & inhibitors
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Ethylamines / pharmacology
  • Ethylenediamines / pharmacology
  • Guanidines / analysis
  • Guanidines / pharmacology*
  • Male
  • Microdialysis / methods
  • Morpholines / pharmacology*
  • Nucleus Accumbens / drug effects*
  • Nucleus Accumbens / metabolism
  • Piperazines / pharmacology
  • Pyrrolidines / pharmacology
  • Radioligand Assay / methods
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, sigma / agonists*
  • Receptors, sigma / antagonists & inhibitors
  • Receptors, sigma / metabolism*
  • Synaptic Transmission / drug effects*

Substances

  • 1-(2-(3,4-dichlorophenyl)ethyl)-4-methylpiperazine
  • 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo(d)oxazol-2(3H)-one
  • Benzoxazoles
  • Dopamine Plasma Membrane Transport Proteins
  • Ethylamines
  • Ethylenediamines
  • Guanidines
  • Morpholines
  • Piperazines
  • Pyrrolidines
  • Receptors, sigma
  • BD 1008
  • 2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate
  • N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin
  • Cocaine
  • 1,3-ditolylguanidine
  • Dopamine